XL184: Additional Phase II data

Additional data from 105 evaluable patients with previously treated GBM in an ongoing, open-label, U.S. Phase II trial showed that there was tumor shrinkage in 82% of the overall trial population and 91% of the antiangiogenic-naïve population. Of 37 antiangiogenic-naïve patients receiving 125 mg daily XL184, 11 had partial responses (PRs) with a median duration of response of 5.1 months, and 25% of patients were progression-free at 6 months. Median PFS was 16 weeks for antiangiogenic-naïve patients and 7.9 weeks for patients with prior antiangiogenic therapy. Of 34 antiangiogenic-naïve patients receiving 175 mg daily XL184, 7 had PRs with a median duration of response of 2.9 months. The trial has enrolled 195 patients. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...